New combo therapy tested for tough transplant complication
NCT ID NCT02340676
Summary
This study tested whether adding a drug called Interleukin-2 (IL-2) to a standard light-based blood treatment (ECP) could help control chronic graft-versus-host disease (GVHD) in adults. The 25 participants had GVHD that did not improve with steroid medications. They received ECP treatments twice a week and added daily IL-2 injections for the second half of a 16-week period to see if the combination was safe and effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Insitute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.